ELEVAI Labs Inc
NASDAQ:ELAB
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
E
|
ELEVAI Labs Inc
NASDAQ:ELAB
|
1.5m USD |
Loading...
|
|
| US |
|
Kenvue Inc
NYSE:KVUE
|
36.4B USD |
Loading...
|
|
| KR |
A
|
APR Co Ltd
KRX:278470
|
11.9T KRW |
Loading...
|
|
| BR |
|
Natura &Co Holding SA
OTC:NTCOY
|
7.7B USD |
Loading...
|
|
| KY |
H
|
Herbalife Ltd
XMUN:HOO
|
5.4B EUR |
Loading...
|
|
| CN |
M
|
Mao Geping Cosmetics Co Ltd
HKEX:1318
|
40.7B HKD |
Loading...
|
|
| KR |
D
|
d'Alba Global Co Ltd
KRX:483650
|
2.1T KRW |
Loading...
|
|
| CN |
|
Runben Biotechnology Co Ltd
SSE:603193
|
9.5B CNY |
Loading...
|
|
| IN |
H
|
Honasa Consumer Ltd
NSE:HONASA
|
99.2B INR |
Loading...
|
|
| CN |
D
|
Dencare Chongqing Oral Care Co Ltd
SZSE:001328
|
7B CNY |
Loading...
|
|
| ID |
|
Industri Jamu dan Farmasi Sido Muncul Tbk PT
IDX:SIDO
|
15.9T IDR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
ELEVAI Labs Inc
Glance View
ELEVAI Labs Inc is a US-based company operating in Personal Care Products industry. The company is headquartered in Newport Beach, California. The company went IPO on 2023-11-21. Elevai Labs, Inc. is a physician-dispensed skincare company. The firm conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. The company produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare products. The company has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for ELEVAI Labs Inc is 27.3%, which is below its 3-year median of 68.8%.
Over the last 2 years, ELEVAI Labs Inc’s Gross Margin has decreased from 67.4% to 27.3%. During this period, it reached a low of 27.3% on Oct 30, 2025 and a high of 94.6% on Sep 30, 2024.
